Product Description
Mechanisms of Action: TCR Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical,Oral,Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Brazil | Chile | Colombia | Dominican Republic | India | Malaysia | Peru | Philippines | Sri Lanka | Turkey | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: EskeC
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Mandibular Diseases|Anesthesia Related|Facial Pain|Inflammation|Poroma|Pain, Postoperative|Osteoarthritis, Knee|Neck Pain|Uterine Hemorrhage
Phase 3: Genital Diseases, Female|Pain, Postoperative|Pulpitis|Dental Caries|Mandibular Fractures|Diabetic Foot
Phase 2: Pulpitis|Dermatitis, Atopic|Environmental Hypersensitivity|Nasal Obstruction|Lacrimal Duct Obstruction|Hypercholesterolemia|Keratoconjunctivitis Sicca|Prostate Cancer|Dry Eye Syndromes|Dental Caries|Sinusitis|Intestinal Diseases|Chronic Pain|Stomatitis, Aphthous
Phase 1: Keratoconjunctivitis Sicca|Periodontal Diseases|Dry Eye Syndromes|Liver Cirrhosis|Psoriasis|Blind Loop Syndrome|Dacryocystitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2200058309 | N/A |
Recruiting |
Infertility |
2040-05-01 |
|
ChiCTR2300078627 | N/A |
Recruiting |
Injuries/wounds Unspecified |
2027-11-01 |
|
ChiCTR2400093518 | N/A |
Not yet recruiting |
Unknown |
2027-09-30 |
|
ChiCTR2400086094 | N/A |
Not yet recruiting |
Oral Ulcer |
2026-12-31 |